MNKD-1501

MNKD-1501 is an investigational drug candidate being developed through a collaboration between **MannKind Corporation** and **United Therapeutics**. The drug utilizes MannKind's proprietary **Technosphere®** platform, a dry-powder inhalation technology designed to deliver medication to the deep lung for rapid systemic absorption or localized pulmonary effect. As of early 2026, the program is in the formulation development stage under an expanded agreement between the two companies. While the specific active pharmaceutical ingredient, biological target, and therapeutic indication have not been publicly disclosed, the partnership between MannKind and United Therapeutics historically focuses on pulmonary orphan diseases, such as pulmonary hypertension.